Format

Send to

Choose Destination
Clin Pharmacol Ther. 2011 Nov;90(5):732-6. doi: 10.1038/clpt.2011.207. Epub 2011 Oct 12.

Blinding in randomized clinical trials: imposed impartiality.

Author information

1
The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark. ah@cochrane.dk

Abstract

Blinding, or "masking," is a crucial method for reducing bias in randomized clinical trials. In this paper, we review important methodological aspects of blinding, emphasizing terminology, reporting, bias mechanisms, empirical evidence, and the risk of unblinding. Theoretical considerations and empirical analyses support the blinding of patients, health-care providers, and outcome assessors as to the trial intervention to which patients have been allocated. We encourage extensive pretrial testing of blinding procedures and explicit reporting of who was in the blinded condition and the methods used to ensure blinding.

PMID:
21993424
DOI:
10.1038/clpt.2011.207
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center